Long-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, India

Bahl, Ankur ; Sharma, Atul ; Raina, Vinod ; Kumar, Lalit ; Bakhshi, Sameer ; Gupta, Ritu ; Kumar, Rajeev (2015) Long-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, India Asia-Pacific Journal of Clinical Oncology, 11 (3). pp. 242-252. ISSN 1743-7555

Full text not available from this repository.

Official URL: http://onlinelibrary.wiley.com/doi/10.1111/ajco.12...

Related URL: http://dx.doi.org/10.1111/ajco.12333


Aim: To analyze clinicopathological characteristics of acute myeloid leukemia (AML) patients and to evaluate long-term outcome of these patients presented to single tertiary care center in India. Methods: We evaluated outcomes of 480 patients (age 8–60 years), classified into good, intermediate and poor risk according to cytogenetic results. Standard “3+7” induction therapy with dose of daunorubicin ranging from 45 to 90 mg/m2 followed by two to three courses of high-dose cytarabine (12–18 g/m2) as consolidation therapy was given to majority. Results: The complete remission rate of the treated population (407 patients) was 70% with 84.8% in good risk, 67.9% in intermediate risk and 54.2% in poor risk (P = 0.0001). Induction mortality was 18.4%. One hundred twenty-nine patients relapsed with median treatment free interval of 10.4 months. At a median follow-up of 34.5 months, the median overall survival (OS) was 20.6 months with an estimated 5-year survival rate of 35.5%. No difference was found in OS between the three risk groups; however, patients with intermediate risk had a better leukemia-free survival (LFS) in comparison to good risk. Multivariate analysis showed age, performance status, treatment completion and hematopoietic stem cell transplant affecting OS, while only treatment completion affected LFS. Conclusion: This is one of the largest single-center studies reflecting more accurately the outcome of AML in India. These results are likely due to uniform treatment protocols, intensification of induction and post-remission treatments with comprehensive supportive care.

Item Type:Article
Source:Copyright of this article belongs to John Wiley and Sons, Inc.
Keywords:Acute Myeloid Leukemia; Cytogenetic; Outcome; Prognostic Factor; Survival
ID Code:111290
Deposited On:25 Sep 2017 12:38
Last Modified:25 Sep 2017 12:38

Repository Staff Only: item control page